Tag Archive

By: Sabrina Serani From: targetedonc.com Key Takeaways Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall response rate compared to chemotherapy. Trastuzumab deruxtecan plus pertuzumab demonstrated significant efficacy in HER2+ breast cancer, marking the first major first-line improvement in over a decade. Emiltatug ledadotin was fast-tracked by the FDA for advanced breast cancer, showing promise …